

Table 10.6i
Immunosuppression Use for Antirejection Treatment from Transplant
to One Year Following Transplantation, 1997 to 2006
Recipients with Intestine Transplants

	Year of Transplant									
	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
Transplants	68	70	73	82	113	107	116	152	178	175
Tx with Antirejection Treatments	46	24	34	45	41	48	66	59	58	61
Antibodies										
Any in Category	17.4%	20.8%	47.1%	48.9%	36.6%	31.3%	37.9%	45.8%	39.7%	63.9%
Atgam/NRATG/NRATS	0.0%	4.2%	0.0%	0.0%	2.4%	2.1%	0.0%	3.4%	3.4%	1.6%
OKT3	17.4%	12.5%	44.1%	31.1%	34.1%	27.1%	27.3%	33.9%	22.4%	41.0%
Thymoglobulin	0.0%	0.0%	11.8%	17.8%	7.3%	6.3%	3.0%	13.6%	10.3%	14.8%
Zenapax	0.0%	4.2%	5.9%	6.7%	0.0%	2.1%	1.5%	1.7%	3.4%	3.3%
Simulect	0.0%	0.0%	0.0%	6.7%	0.0%	0.0%	0.0%	0.0%	0.0%	1.6%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	8.3%	15.2%	6.8%	3.4%	8.2%
Corticosteroids										
Any in Category	93.5%	91.7%	85.3%	75.6%	80.5%	95.8%	92.4%	93.2%	86.2%	82.0%
Steroids	93.5%	91.7%	85.3%	75.6%	80.5%	95.8%	92.4%	93.2%	86.2%	82.0%
Antimetabolites										
Any in Category	0.0%	0.0%	0.0%	0.0%	2.4%	0.0%	0.0%	0.0%	1.7%	0.0%
Cytosan	0.0%	0.0%	0.0%	0.0%	2.4%	0.0%	0.0%	0.0%	1.7%	0.0%
Methotrexate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.